Effectiveness of Colchicine Among Patients With COVID-19 Infection
Coronavirus Infection
About this trial
This is an interventional treatment trial for Coronavirus Infection focused on measuring covid-19, colchicine, Erbil,Iraq
Eligibility Criteria
Inclusion Criteria:
1.patients diagnosed clinically or by RT-PCR in nasopharyngeal swab specimens and/ or lung involvement confirm by computed tomography scan compatible with COVID-19patients 2.Age between 18 year and 70 years, 3.body weight > 50 kg, 4.with written informed consent from patients or relatives.
-
Exclusion Criteria 1 sensitivity to any medications of regimens, 2.e GFR less than 30. 3.pregnancy. 4.malignancy . 5.Participating in another clinical study and refusing to participate in the study at a later date or later, and they are already taking colchicine for other diseases .
-
Sites / Locations
- Hawler medical university ,Rozhawa emergency hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
colchicine drug
usual care
participant in this group will be given a colchicine tablet alone or add to their Current treatment, Colchicine 0.5 mg twice daily (reduced to 0.5 mg/day, in patients with low body weight or develop side effect like gastrointestinal symptoms ),For 14 days or until symptoms subsides.
control group will receive usual care COVID-19 treatment according to Iraqi protocol guideline and will not receive colchicine.